Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
Published Date: 17 Feb 2023
More than 2.5 million agricultural workers help maintain America's food supply. They play an important role in the economy, but their work is difficult and often dangerous.
Read Full NewsALOFT-IPF: Admilparant 60 mg Meets Primary FVC End Point
Carmela Tartaglia, MD, FRCPC, discusses the challenges of diagnosing frontotemporal dementia, the evolving role of biomarkers, and emerging approaches to disease modification.
Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending October 9, 2026.
Why patients with IgA nephropathy want to understand their disease, not just follow instructions.
Phase 3 ABTECT data show ~51% clinical remission and ≥40% endoscopic remission with obefazimod through week 44.
Obefazimod could work as first, second, or third line therapy in ulcerative colitis ahead of a planned FDA submission this year.
Arjan Bredenoord, MD, details how tezepelumab's selective TSLP inhibition sustained EoE remission through week 52 of the CROSSING trial.
1.
Novel Treatment Shows Promise for Oral Mucositis Caused by Radiation.
2.
When BCG is not effective in treating bladder cancer, Oncolytic Virus exhibits high response rates.
3.
Upping Immunotherapy Activity; A Win for Lung Screening; Looming Drug Price Break?
4.
Urinary tract cancer prediction models with high sensitivity and specificity
5.
Mapping lifelong chronic health risks for childhood cancer survivors
1.
Modern Updates in Hematology in the Digital Era
2.
Mechanisms of Tumor Cell Plasticity During Metastatic Spread
3.
Oral Treatment Strategies in Psoriasis & Melasma: Where Are We Heading?
4.
The Science Behind Thrombolytic Drugs and Their Benefits
5.
Unlocking the Mystery of Hemoglobin C Trait: A Closer Look at a Rare Blood Disorder
1.
International Conference on Oncology, Cardiology and Critical Care Policy
2.
International Conference on Innovations in Critical Care for Oncology and Cardiology
3.
International Conference on Oncology, Cancer Prevention and Public Health
4.
International Conference on Cancer Nursing and Rehabilitation Strategies
5.
International Conference on Cancer Nursing and Hematology Support
1.
Deep Dive Into EGFR Mutation Positive Non-Small Cell Lung Cancer
2.
Post Progression Approaches After First-line Third-Generaion ALK Inhibitors
3.
Lorlatinib in the Management of 1st line ALK+ mNSCLC (CROWN TRIAL Update) - Conclusion
4.
Untangling The Best Treatment Approaches For ALK Positive Lung Cancer - Part VII
5.
Revolutionizing Treatment of ALK Rearranged NSCLC with Lorlatinib - Part III
Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
To get started please enter your email ID
Join to enhance your clinical skills and gain specialized in-depth medical knowledge